[go: up one dir, main page]

AU2003246414A8 - Preparations for the intranasal application of selected cgrp antagonists derived from amino acids and a method for their production - Google Patents

Preparations for the intranasal application of selected cgrp antagonists derived from amino acids and a method for their production

Info

Publication number
AU2003246414A8
AU2003246414A8 AU2003246414A AU2003246414A AU2003246414A8 AU 2003246414 A8 AU2003246414 A8 AU 2003246414A8 AU 2003246414 A AU2003246414 A AU 2003246414A AU 2003246414 A AU2003246414 A AU 2003246414A AU 2003246414 A8 AU2003246414 A8 AU 2003246414A8
Authority
AU
Australia
Prior art keywords
preparations
production
amino acids
intranasal application
cgrp antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003246414A
Other versions
AU2003246414A1 (en
Inventor
Ulrich Busch
Bernd Kruss
Klaus Jost
Marc A Gaiser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG, Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Publication of AU2003246414A1 publication Critical patent/AU2003246414A1/en
Publication of AU2003246414A8 publication Critical patent/AU2003246414A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A pharmaceutical composition (I) for intranasal administration as aqueous solution contains a specific piperazine or piperidine derivative active agents (2-25 w/v%) (A) and at least one equivalent of a solubilizing acid (B) to convert (A) into a salt which dissolves in anionic form. An independent claim is included for the preparation of (I). ACTIVITY : Antimigraine. MECHANISM OF ACTION : Calcitonin gene-related peptide (CGRP) antagonist.
AU2003246414A 2002-06-19 2003-06-12 Preparations for the intranasal application of selected cgrp antagonists derived from amino acids and a method for their production Abandoned AU2003246414A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10227294A DE10227294A1 (en) 2002-06-19 2002-06-19 Preparations for intranasal application of selected amino acid-derived CGRP antagonists and processes for their preparation
DE10227294.8 2002-06-19
PCT/EP2003/006156 WO2004000289A2 (en) 2002-06-19 2003-06-12 Preparations for the intranasal application of selected cgrp antagonists derived from amino acids and a method for their production

Publications (2)

Publication Number Publication Date
AU2003246414A1 AU2003246414A1 (en) 2004-01-06
AU2003246414A8 true AU2003246414A8 (en) 2004-01-06

Family

ID=29719240

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003246414A Abandoned AU2003246414A1 (en) 2002-06-19 2003-06-12 Preparations for the intranasal application of selected cgrp antagonists derived from amino acids and a method for their production

Country Status (8)

Country Link
EP (2) EP1517674B1 (en)
JP (1) JP2005530830A (en)
AT (1) ATE359059T1 (en)
AU (1) AU2003246414A1 (en)
CA (1) CA2487716A1 (en)
DE (2) DE10227294A1 (en)
ES (1) ES2283820T3 (en)
WO (1) WO2004000289A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7595312B2 (en) 2002-10-25 2009-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
DE10300973A1 (en) * 2003-01-14 2004-07-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg New carboxylic acids and their esters, medicaments containing these compounds and processes for their preparation
WO2005084672A1 (en) * 2004-03-03 2005-09-15 Boehringer Ingelheim International Gmbh Selected cgrp-antagonists, method for the production and use thereof as medicaments
DE102004015723A1 (en) 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Selected CGRP antagonists, process for their preparation and their use as pharmaceuticals
DE102004018796A1 (en) * 2004-04-15 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Selected CGRP antagonists, process for their preparation and their use as pharmaceuticals
DE102004018795A1 (en) * 2004-04-15 2005-10-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Selected CGRP antagonists, process for their preparation and their use as pharmaceuticals
US7439237B2 (en) 2005-04-15 2008-10-21 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0927192T3 (en) * 1996-09-10 2004-09-13 Boehringer Ingelheim Pharma Modified amino acids, drugs containing these compounds and methods for their preparation
DE19911039A1 (en) * 1999-03-12 2000-09-14 Boehringer Ingelheim Pharma Modified amino acid amides, pharmaceutical compositions containing these compounds and process for their preparation
DE19937304C2 (en) * 1999-08-10 2003-08-21 Boehringer Ingelheim Pharma Use of CGRP antagonists to combat menopausal hot flashes

Also Published As

Publication number Publication date
JP2005530830A (en) 2005-10-13
ES2283820T3 (en) 2007-11-01
DE50307025D1 (en) 2007-05-24
EP1517674A2 (en) 2005-03-30
AU2003246414A1 (en) 2004-01-06
EP1769790A1 (en) 2007-04-04
DE10227294A1 (en) 2004-01-08
CA2487716A1 (en) 2003-12-31
ATE359059T1 (en) 2007-05-15
EP1517674B1 (en) 2007-04-11
WO2004000289A2 (en) 2003-12-31
WO2004000289A3 (en) 2004-03-25

Similar Documents

Publication Publication Date Title
Medeiros et al. Processing and metabolism of peptide-YY: pivotal roles of dipeptidylpeptidase-IV, aminopeptidase-P, and endopeptidase-24.11
EE04911B1 (en) The compound and the pharmaceutical composition as protease inhibitors, their use and a method for preparing the compound
WO2001080897A3 (en) Compositions and methods for in vivo delivery of polynucleotide-based therapeutics
CR10114A (en) PHARMACEUTICAL COMPOSITIONS THAT INCLUDE INHIBITORS OF HMG COA REDUCTASA (DIVISIONAL OF EXP. 6687)
ATE449174T1 (en) NEW PEPTIDES
BRPI0112859B8 (en) somatostatin analogues, pharmaceutical composition, as well as the use of said analogues
NZ597260A (en) Formulations for parenteral delivery of compounds and uses thereof comprising methylnaltrexone
MY172823A (en) Formulation of human antibodies for treating tnf-() associated disorders
IL189371A0 (en) A method for conversion of insoluble glucagon-like peptide (glp-1) compounds to a soluble glp-1 compound
BR0306685A (en) Pharmaceutical composition containing ghrelin
WO2011143406A2 (en) Parathyroid hormone analogs and uses thereof
AU2003246414A8 (en) Preparations for the intranasal application of selected cgrp antagonists derived from amino acids and a method for their production
TW200735897A (en) HFSH aqueous formulation
SE0002202D0 (en) New peptides
EP0358234A2 (en) Intranasal calcitonin formulations
EP2349312B1 (en) N-terminally modified tetrapeptide derivatives having a c-terminal arginine mimetic
NO20052041L (en) Method of administration for sustained release pharmaceutically active peptides and process for their preparation
IS5851A (en) New Oral 5-HT4 Agents or Antagonists
BR0009472A (en) Lhrh antagonists with improved solubility properties
DE60301878D1 (en) PHARMACEUTICAL COMPOSITION CONTAINING ALPHA-KETOALKANIC ESTER OR AMID AND MILKY ACID OR MILKIC ACID SALT
Cochrane et al. Rapid degradation of neurotensin by stimulated rat mast cells
MY136546A (en) A pharmaceutical component based on human parathyroid harmone and a pharmaceutical composition for intranasal administration comprising the component
DK1268522T3 (en) LH-RH antagonists as well as their preparation and use thereof as drugs
JP2012522787A (en) Peptide pharmaceutical composition for nasal delivery
DE60001489D1 (en) PHARMACEUTICAL PREPARATION FOR THE INTRAVENOUS OR INTRAMUSCULAR ADMINISTRATION OF OCTREOTIDE

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase